Elevated expression of GIV has also been reported in a variety of solid tumors (Garcia‐Marcos et al, 2015; Getz et al, 2019), both in primary tumors (Ghosh, 2015; Ghosh et al, 2016b) as well as in circulating tumor cells (Barbazan et al, 2016; Dunkel et al, 2018), and has been shown to correlate with tumor aggressiveness and poor survival across cancers. The gene discussed is CCDC88A; the disease is neoplasm.